Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida Nebraska Cancer Specialists, Omaha, Nebraska Columbia University Irving Medical Center, New York, New York Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania Sarah Cannon Research Institute, Nashville, Tennessee